3-Oxo-undecanal | 132869-18-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-Oxo-undecanal
• 英文别名: Undecane-1,3-dione；3-oxoundecanal
• CAS: 132869-18-2
• 化学式: C₁₁H₂₀O₂
• 分子量: 184.279
• InChiKey: VRQQIOLPJVLMPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  13
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,1,3-Tribromoundecane 在 镍 氢气 、 溶剂黄146 、 sodium nitrite 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 3-Oxo-undecanal
  参考文献：
  名称：

  Dasaradhi, L.; Rao, S. Jagadishwar; Bhalerao, U.T., Synthetic Communications, 1990, vol. 20, # 18, p. 2799 - 2804

  摘要：

  DOI：

文献信息

• Immunosuppressant n-acyles homoserine lactones
  申请人：——

  公开号：US20030171371A1

  公开（公告）日：2003-09-11

  New N-acyl homoserine lactone compounds of the formula (I) in whichR is an acyl group of the formula (II) wherein one of R 1 and R 2 is H and the other is selected from OR 4 , SR 4 and NHR 4 , wherein R 4 is H or 1-6C alkyl, or R 1 and R 2 together with the carbon atom to which they are joined form a keto group, and R 3 containing from 8 to 11 carbon atoms and is optionally substituted by one or more substituent groups selected from halo, 1-6C alkoxy, carboxy, 1-6C alkoxycarbonyl, carbamoyl optionally mono- or disubstituted at the N atom by 1-6C alkyl and NR 5 R 6 wherein each of R 5 and R 6 is selected from H and 1-6C alkyl or R 5 and R 6 together with the N atom form a morpholino or piperazino group, or and enantiomer thereof, with the proviso that R is not a 3-oxododecanoyl group, having immuosuppressant properties are disclosed. The compounds are shown to have an inhibitory effect on lymphocyte proliferation and down-regulate TNF-&agr; secretion by monocytes/macrophages in the animal body, including the human body. Pharmaceutical composition comprising N-acyl homoserine lactones are also described. 1

  公开了式(I)的新的N-酰基高丝氨酸内酯化合物，其中R是式(II)的酰基，其中R1和R2中的一个为H，另一个选择自OR4、SR4和NHR4，其中R4为H或1-6C烷基，或者R1和R2与它们结合的碳原子一起形成酮基，而R3含有8至11个碳原子，并且可以被一个或多个取代基选自卤素、1-6C烷氧基、羧基、1-6C烷氧羰基、在N原子上可能被1-6C烷基单独或二取代的氨基和NR5R6，其中R5和R6中的每一个选择自H和1-6C烷基或R5和R6与N原子一起形成吗啡环或哌嗪环，或其对映体，但R不是3-氧代十二酰基基团。这些化合物具有免疫抑制特性，已经表明这些化合物对淋巴细胞增殖具有抑制作用，并且在动物体内，包括人体内，下调单核细胞/巨噬细胞的TNF-α分泌。还描述了包含N-酰基高丝氨酸内酯的制药组合物。
• Synergistic compositions of n-acylhomoserine lactones and 4-quinolones
  申请人：——

  公开号：US20040198978A1

  公开（公告）日：2004-10-07

  A composition having immunosuppressant activity comprises at least one compound of the formula (I) in which R is an acyl group of the formula (II) wherein one of R 1 and R 2 is H and the other is selected from OR 4 , SR 4 and NHR 4 , wherein R 4 is H or 1-6C alkyl, or R 1 and R 2 together with the carbon atom to which they are joined form a keto group, and R 3 is a straight or branched chain, saturated or unsaturated aliphatic hydrocarbyl group containing from 8 to 11 carbon atoms and is optionally substituted by one or more substituent groups selected from halo, 1-6C alkoxy, carboxy, 1-6C alkoxycarbonyl and NR 5 R 6 wherein each of R 5 and R 6 is selected from H and 1-6C alkyl or R 5 and R 6 together with the N atom form a morpholino or piperazino group, or any enantiomer thereof; and at least one compound of the formula (III): wherein R 7 is a straight or branched chain, saturated or ethylenically-unsaturated aliphatic hydrocarbyl group containing from 1 to 18 carbon atoms which may optionally be substituted by one or more substituent groups selected from halo, 1-6C alkoxy, carboxy, 1-6C alkoxycarbonyl and NR 12 R 13 , wherein each of R 12 and R 13 is independently selected from H and 1-6C alkyl or R 12 and R 13 together with the N atom to which they are attached form a saturated heterocyclic group selected from piperidino, piperazino and morpholino; R 8 is a group selected from H, —OH, halo, —CHO, —CO 2 H and CONHR 14 wherein R 14 is H or a 1-6C alkyl; each of R 9 , R 10 and R 11 is independently selected from H, —CH 3 , —OCH 3 and halo; or a non-toxic pharmaceutically-acceptable salt thereof. The determined immunosuppressant activity of the composition is greater than the sum of the activities of the individual components of the composition when determined separately. 1

  具有免疫抑制活性的组合物包括公式（I）中至少一种化合物，其中R是公式（II）的酰基，其中R1和R2中的一个是H，另一个选自OR4，SR4和NHR4，其中R4是H或1-6C烷基，或者R1和R2与它们连接的碳原子形成酮基，R3是含有8至11个碳原子的直链或支链、饱和或不饱和的脂肪族羟基烷基，可选地被一个或多个取代基选自卤素，1-6C烷氧基，羧基，1-6C烷氧羰基和NR5R6取代，其中每个R5和R6选自H和1-6C烷基或R5和R6与N原子形成吗啉或哌嗪基团，或其任何对映体；以及公式（III）中的至少一种化合物：其中R7是含有1至18个碳原子的直链或支链、饱和或乙烯不饱和的脂肪族羟基烷基，可以选择地被一个或多个取代基选自卤素，1-6C烷氧基，羧基，1-6C烷氧羰基和NR12R13取代，其中每个R12和R13独立地选自H和1-6C烷基或R12和R13与它们附着的N原子形成选自哌啶基，哌嗪基和吗啉的饱和杂环基；R8是选自H，—OH，卤素，—CHO，—CO2H和CONHR14的基团，其中R14是H或1-6C烷基；每个R9、R10和R11独立地选自H、—CH3、—O 和卤素；或其非毒性药物可接受盐。当单独测定时，组合物的确定免疫抑制活性大于组合物各个组分的活性之和。
• Apoptosis inducer and method of screening for a substance inhibiting acylated homoserine lactone
  申请人：Nomura, Nobuhiko

  公开号：EP1442742A1

  公开（公告）日：2004-08-04

  The present invention relates to an Akt inhibitor comprising a compound represented by formula I: [wherein R is C4-30 linear or branched acyl, which may be substituted.] The present invention further relates to a method of screening for a substance inhibiting acylated homoserine lactone by culturing animal cells with a test substance in the presence of acylated homoserine lactone represented by the above formula I, and then detecting inhibition of Akt activity or inhibition of the survival signalling pathway in which Akt is involved in the cells.

  本发明涉及一种 Akt 抑制剂，包括由式 I 所代表的化合物： [其中R为C4-30直链或支链酰基，可被取代。] 本发明进一步涉及一种筛选抑制酰化高丝氨酸内酯的物质的方法，该方法是在有上述式I代表的酰化高丝氨酸内酯存在的情况下，用试验物质培养动物细胞，然后检测细胞中Akt活性的抑制情况或Akt参与的生存信号通路的抑制情况。
• Modulation of stat activity
  申请人：——

  公开号：US20040259942A1

  公开（公告）日：2004-12-23

  The use of a compound selected from a range of compounds including quorum sensing molecules, N-acyl homo serine lactones, N-(3-oxododecanoyl)-L-homoserine lactone, inhibitors to modulate STAT activity for the treatment of a range of diseases including cancer, breast cancer, obesity, lipid metabolism disorders, immune disease, immune deficiency or immune disorders. The range of compounds also include compounds of formula (I) in which R is an acyl group of formula (II). 1

  选自一系列化合物的化合物，包括定量感应分子、N-酰基同丝氨酸内酯、N-(3-氧代十二酰基)-L-高丝氨酸内酯、调节 STAT 活性的抑制剂，用于治疗一系列疾病，包括癌症、乳腺癌、肥胖症、脂质代谢紊乱、免疫疾病、免疫缺陷或免疫紊乱。这一系列化合物还包括式（I）化合物，其中 R 为式（II）酰基。 1
• Use of n-acyl homoserine lactones for the treatment of insulitis
  申请人：Pritchard Idris David

  公开号：US20050014751A1

  公开（公告）日：2005-01-20

  An immune response modulatory compound is described. The compound has been shown to inhibit lymphocyte proliferation and to down-regulate TNF-secretion by monocytes and/or macrophages with the consequent activation of Th 1 lymphocytes in humans or other animals.

  本文描述了一种免疫反应调节化合物。研究表明，该化合物可抑制淋巴细胞增殖，下调单核细胞和/或巨噬细胞分泌的 TNF，从而激活人类或其他动物体内的 Th 1 淋巴细胞。